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Background: Hepatitis B virus (HBV) genotypes have a distinct geographical distribution and influence disease
progression and treatment outcomes. The purpose of this study was to investigate the distribution of HBV
genotypes in Europe, the impact of mutation of different genotypes on HBV gene abnormalities, the features of
CpG islands in each genotype and their potential role in epigenetic regulation.
Results: Of 383 HBV isolates from European patients, HBV genotypes A-G were identified, with the most frequent
being genotype D (51.96%) in 12 countries, followed by A (39.16%) in 7 countries, and then E (3.66%), G (2.87%), B
(1.57%), F (0.52%) and C (0.26%). A higher rate of mutant isolates were identified in those with genotype D (46.7%)
followed by G (45.5%), and mutations were associated with structural and functional abnormalities of HBV genes.
Conventional CpG island I was observed in genotypes A, B, C, D and E. Conventional islands II and III were detected
in all A-G genotypes. A novel CpG island IV was found in genotypes A, D and E, and island V was only observed in
genotype F. The A-G genotypes lacked the novel CpG island VI. “Split” CpG island I in genotypes D and E and “split”
island II in genotypes A, D, E, F and G were observed. Two mutant isolates from genotype D and one from E were
found to lack both CpG islands I and III.
Conclusions: HBV genotypes A-G were identified in European patients. Structural and functional abnormalities of
HBV genes were caused by mutations leading to the association of genotypes D and G with increased severity of
liver disease. The distribution, length and genetic traits of CpG islands were different between genotypes and their
biological and clinical significances warrant further study, which will help us better understand the potential role of
CpG islands in epigenetic regulation of the HBV genome.
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Hepatitis B virus (HBV) infection is a serious health
problem worldwide. The World Health Organization
(WHO) has estimated that around 240 million people
globally are chronically infected with HBV, which cause
between 500,000 and 700,000 deaths annually [1]. In
much of the developing world, (sub-Saharan Africa,
most of Asia, and the Pacific), 8% to 10% of people in
the general population become chronically infected.
Although HBV infection is less common in Western
Europe, a recent investigation by the European Centre for
Disease Prevention and Control showed an unexpected* Correspondence: yzhong2014@126.com
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unless otherwise stated.increase in HBV infection between 1995 and 2005 with an
incidence from 0.7% to 5.3% [2,3].
HBV belongs to the genus Orthohepadnavirus of the
Hepadnaviridae family and has a circular genome of
approximately 3.2 kb in length. Because of its long history
of co-evolution with humans, HBV has evolved as multiple
genetic strains that are present at different rates in human
populations [4]. Based on a minimum divergence of 8% of
the complete genome sequences, HBV is classified as
different genotypes consecutively identified as genotypes
A–J [4-6]. The genotypes have a distinct geographical
distribution. In Europe, genotypes A and D are the main
genotypes, and genotype A is more prevalent in northern
and central Europe [7], whereas genotype D is mainly
found in countries surrounding the Mediterranean Sea and
in Eastern Europe [7]. Genotype G was detected in HBV
carriers from Germany [8], Netherlands [9] and GeorgiaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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frequent being genotypes D (27%) and A (24%), followed
by E (13%) and C (12%), and B (7%) [11,12]. HBV ge-
notypes are used to trace the evolution and transmis-
sion of the virus. Differences between genotypes affect
the disease severity, disease course and likelihood of
complications, as well as response to treatment and
possibly to vaccination [5].
Besides genotypes, specific HBV viral mutations ap-
pear to strongly influence the outcome of HBV infection.
HBV replicates through reverse transcription of an RNA
intermediate. Because the reverse transcriptase activity
of the HBV polymerase protein lacks a proofreading
function, random mis-incorporation of bases into the
replicating DNA strand occurs, leading to a high muta-
tion rate. In addition, mutations occur as a consequence
of selection pressure by the host’s immune system and/
or by exogenous factors such as active or passive vaccin-
ation or drug therapy [6,13].
DNA methylation is being increasingly recognized to
play a role in the regulation of viral gene expression. It
was demonstrated that HBV DNA can be methylated in
human tissue in both a nonintegrated form [14] and fol-
lowing integration into the human genome [15]. DNA
methylation typically occurs in a CpG dinucleotide con-
text that is often grouped in clusters called CpG islands.
Hypermethylation of CpG islands located in promoter
regions are involved in gene silencing at the transcrip-
tional level [16]. The HBV genome contains four pro-
moter elements (sp1, sp2, cp and xp), and two enhancer
elements (Enh I and Enh II) that control four defined
overlapping open reading frames (pre-S/S, core/e, X, and
P genes), which promote transcription and expression of
the seven different hepatitis B proteins. Many studies
have demonstrated that HBV DNA contains three pre-
dicted CpG islands termed conventional CpG islands I,
II and III. Recently, Zhang et al. identified three novel CpG
islands in 14 of 176 HBV isolates and named them
CpG islands IV, V, and VI [6]. Hou et al. also detected
CpG islands at the same locations in 30 of 320 HBV
isolates from Chinese patients (data not shown).
In the present study, the mutant sequence, as well as
the location, distribution, length and genetic traits of
CpG islands of different HBV genotypes isolated from
the European patients were investigated to help us better
understand the impact of mutation on gene expression
among genotypes and the potential role of CpG islands
in the epigenetic regulation of the HBV genome.
Methods
Nucleotide sequences of HBV genomes were searched from
GenBank using an updated database (last accessed on 31
January 2014) at the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/nucleotide), using“Hepatitis B virus”, “complete genome” and “genotype X”
(X represents A, B, C, D, E, F or G) as the terms for search
query. Full-length HBV genome sequences of genotypes A
through G from European countries were retrieved. The
background information consisted of an assessment of gen-
ome length, regions, genotype, resource, open reading
frame (ORF) location and gene function. HBV genome se-
quences were manually excluded from the database when
they were shorter than 3050 base pairs (bp), or had incom-
plete background information [17].
Multiple alignments of the 383 HBV sequences, contain-
ing complete functional genes or defined gene mutations,
were conducted using the CLUSTALX 1.83 program
(UCD Conway Institute, Dublin, Ireland). The genotype of
each analyzed sequence was compared with the original
report to confirm the background genotyping information.
If a discrepancy existed between the observed data and
the original report, updated information was collected for
further analysis.
CpG islands were analyzed using MethPrimer (http://
www.urogene.org/methprimer/index1.html) by examining
the GC content and the observed-to-expected ratio in a
window size. The location and size of CpG islands within
each analyzed sequence were identified according to the
current knowledge of CpG island distributions in the HBV
genomes [18]. Because each genotype contains multiple se-
quences and the lengths of the sequences are different,
we calculated the length of CpG island of each geno-
type according to their location in the sequence: the
most proximal site of the CpG island in the sequence
was designated the start and the most distal site was
designated the end. To identify each CpG island, the
following criteria were defined: a GC content of 0.50
or greater; an observed-to-expected CpG dinucleotide
ratio of 0.60 or greater; and both occurring within a se-
quence window of 100 bps or greater [6,14,19].
Results
Geographical distribution of HBV genotypes in Europe
A total of 383 HBV isolates were identified as 7 datasets:
genotype A (n = 150, 39.16%), B (n = 6, 1.57%), C (n = 1,
0.26%), D (n = 199, 51.96%), E (n = 14, 3.66%), F (n = 2,
0.52%) and G (n = 11, 2.87%). Genotype A isolates were
observed in 7 countries including Belgium (n = 72, 48%),
Poland (n = 45, 30%), Germany (n = 13, 8.6%), Russia
(n = 8, 5.3%), France (n = 4, 2.7%), Latvia (n = 4, 2.7%)
and Estonia (n = 4, 2.7%). Genotype D isolates were
from 12 countries including Turkey (n = 93, 46.7%),
Belgium (n = 28, 14.1%), Russia (n = 20, 10.2%), Estonia
(n = 13, 6.5%), Italy (n = 12, 6.0%), Greenland (n = 10,
5.0%), Poland (n = 8, 4.0%), Sweden (n = 4, 2.0%), Germany
(n = 3, 1.5%), France (n = 3, 1.5%), Serbia (n = 3, 1.5%)
and Spain (n = 2, 1.0%). Genotypes B, C, E, F and G
were from 2, 1, 4, 1 and 4 countries, respectively.
Figure 1 Geographical distribution of HBV genotypes in some European countries. BE: Belgium, BO: Bolivia, DE: Germany, EE: Estonia,
ES: Spain, FR: France, GL: Greenland, IT: Italy, LV: Latvia, NL: Netherland, PL: Poland, RS: Serbia, RU: Russia, SE: Sweden, TR: Turkey, UK: United Kingdom.
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types in different European countries are shown in Figure 1.
Mutations among HBV genotypes in Europe
Genotype A consisted of 123 normal and 27 mutant iso-
lates. Genotype B consisted of 6 normal isolates. GenotypeTable 1 The normal and mutant isolates in the different geno
Countries Genotype A Genotype B Genotype C
Nor Mut Nor Mut Nor Mut
Belgium 68 4 1 - 1 -
Bolivia - - - - - -
Estonia 4 - - - - -
France 4 - - - - -
Germany 10 3 - - - -
Greenland - - 5 - - -
Italy - - - - - -
Latvia 3 1 - - - -
Netherland - - - - - -
Poland 26 19 - - - -
Russia 8 - - - - -
Serbia - - - - - -
Spain - - - - - -
Sweden - - - - - -
Turkey - - - - - -
United kingdom - - - - - -
Sum 123 27 6 0 1 0
Nor: normal sequence; Mut: mutant sequence.C consisted of 1 normal isolate. Genotype D consisted of
106 normal and 93 mutant isolates. Genotype E consisted
of 12 normal and 2 mutant isolates. Genotype F consisted
of 2 normal isolates. Genotype G consisted of 6 normal
and 5 mutant isolates. Genotype A isolates were mainly
from Belgium (68 normal and 4 mutant isolates) andtypes in some countries in Europe
Genotype D Genotype E Genotype F Genotype G
Nor Mut Nor Mut Nor Mut Nor Mut
10 18 5 2 - - - 3
- - - - 2 -
12 1 - - - - - -
2 1 - - - - 1 1
1 2 2 - - - 2 -
10 - - - - - - -
12 - - - - - - -
- - - - - - - -
- - - - - - 3 1
2 6 - - - - - -
18 2 - - - - - -
2 1 - - - - - -
2 - - - - - - -
3 1 - - - - - -
32 61 - - - - - -
- - 5 - - - - -
106 93 12 2 2 0 6 5
Table 2 The number and percentage of the mutant isolates with the structural or functional abnormalities in the
genotypes




A 26 96% (1) The truncated proteins including pre-C/C, pre-S1/pre-S2/S and X proteins; (2) the nonfunctional
proteins including pre-C/C, pre-S2/S and X proteins; (3) the proteins containing aa internal deletion
including pre-C/C and pre-S1/pre-S2/S proteins; (4) X gene containing a point mutation which
resulted in a premature stop codon.
26/27
D 27 29% (1) The truncated proteins including pre-C/C, pre-S1/pre-S2/S and X proteins; (2) the nonfunctional
proteins including pre-C/C, pre-S1/pre-S2/S, X proteins and polymerase; (3) the proteins containing
aa internal deletion including pre-C/C and pre-S1/pre-S2/S proteins; (4) pre-C/C and X genes
containing a point mutation which resulted in a premature stop codon; (5) some pre-C/C genes
were pseudogenes.
27/93
E 2 100% (1) The truncated pre-C/C protein; (2) the nonfunctional proteins including pre-C/C, polymerase
and large S proteins.
2/2
G 4 80% (1) The truncated X protein; (2) the nonfunctional pre-C/C protein; (3) pre-C/C containing a
premature stop codon.
4/5
*The percentage is equal to number of the mutant isolates with the structural or functional abnormalities/number of total mutant isolates × 100%.
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D isolates were mainly from Turkey (32 normal and 61
mutant isolates) and Belgium (10 normal and 18 mutant
isolates). Detailed distribution of the normal and mutant
isolates in different European countries is shown in Table 1.
Some mutant isolates in genotypes A, D, E and G were
associated with structural and functional abnormalities
of HBV genes, including truncated proteins, nonfunc-
tional proteins, proteins containing amino acid (aa) in-
ternal deletions, genes containing a point mutation, and
pseudogenes. The number and percentage of mutant
isolates with structural or functional abnormalities in
each genotype are shown in Table 2.
Location and length differences of CpG islands among
HBV genotypes A-G
In the present study, CpG island I in A, B, C, D and E
genotypes were located at nucleotides 76–291, 108–287,
186–286, 77–432 and 72–286, respectively, which spanned
the start site of the S gene. CpG island II in A, B, C, D, E, F
and G genotypes were located at nucleotides 1113–1674,Table 3 The location and length of CpG islands in HBV Genot











A 76-291 216 1113-1674 562 2185-
B 108-287 180 1139-1673 535 2298-
C 186-286 101 1219-1663 445 2280-
D 77-432 356 1100-1674 575 2188-
E 72-286 215 1212-1674 463 2172-
F - - 1216-1673 458 2298-
G - - 1160-1628 469 2304-
Genotype VI was not observed in all listed genotypes.1139–1673, 1219–1663, 1100–1674, 1212–1674, 1216–
1673 and 1160–1628, respectively, which covered the par-
tial Enh I and X promoter, located immediately upstream
of the Enh II/core gene promoters. CpG island III in A, B,
C, D, E, F and G genotypes were located at nucleotides
2185–2466, 2298–2462, 2280–2442, 2188–2465, 2172–
2458, 2298–2458 and 2304–2497, respectively, which cov-
ered the partial C gene and encompassed the start site of
the P gene. CpG island IV in A, D and E genotypes were
located at nucleotides 529–632, 443–589, 471–573, re-
spectively, which were located between CpG islands I and
II, in a region overlapping the S and P genes [6,20]. Island
V was only observed in genotype F, located at nucleotides
1921–2038 and between CpG islands II and III, in a region
overlapping the C genes. CpG islands VI was not observed
in genotypes A-G (Table 3; Figure 2F-H).
Distribution and genetic trait of CpG islands in HBV
genotypes A-G
In a total of 383 isolates, three lacked both CpG island I
and III, which were excluded from the distributionypes A–G











2466 282 529-632 104 - -
2462 165 - - - -
2442 163 - - - -
2465 278 443-589 147 - -
2458 287 471-573 103 - -
2458 161 - - 1921-2038 118
2497 194 - - - -
Figure 2 The CpG island distribution within representative HBV sequences of HBV genotypes A-G. The open reading frames of the pre-core/core,
polymerase, surface antigen, and X genes are indicated as blue arrows. The four promoters, xp, cp, sp1 and sp2, are indicated as solid yellow circles, and
the main regulatory elements, enhancers I and II (Enh I and Enh II), are indicated as green boxes. The light blue areas represent the predicted methylation
region of CpG islands within the HBV genome. The light blue boxes containing vertical lines represent CpG islands I to V within the HBV genome.
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two normal isolates of genotype F contained both two-
conventional islands and novel island V, which were used
twice for calculating the rates (Table 4; Figure 2G). The
majority of isolates contained the three-conventional CpG
islands (I, II and III) (69.21%, 263/380) (Figure 2E), followedby isolates containing the two-conventional CpG islands
(II and III) (28.42%, 108/380) (Figure 2D), and then by
isolates containing the novel islands (2.89%, 11/380). In
genotype B, no mutant isolates and novel CpG islands
were observed, while genotype C had only one normal
sequence, which contained three-conventional islands. No
Table 4 Distribution of CpG islands in HBV genotypes A-G
Genotype Three-conventional CpG islands Two-conventional CpG islands Novel CpG islands
number % number % number %
A total 115 76.66% 31 20.67% 4 2.67%
(n = 150)
A normal 100 81.30% 21 17.07% 2 1.63%
(n = 123)
A mutant 15 55.56% 10 37.04% 2 7.40%
(n = 27)
B total 4 66.7% 2 33.3% 0 0
(n = 6)
B normal 4 66.7% 2 33.3% 0 0
(n = 6)
B mutant 0 0 0 0 0 0
(n = 0)
C total 1 100% 0 0 0 0
(n = 1)
C normal 1 100% 0 0 0 0
(n = 1)
C mutant 0 0 0 0 0 0
(n = 0)
D total 135 68.53% 59 29.95% 3 1.52%
(n = 197)*
D normal 71 66.98% 34 32.08% 1 0.94%
(n = 106)
D mutant 64 70.33% 25 27.47% 2 2.20%
(n = 91)*
E total 8 61.54% 3 23.08% 2 15.38%
(n = 13)*
E normal 8 66.66% 2 16.67% 2 16.67%
(n = 12)
E mutant 0 0 1 100% 0 0
(n = 1)*
F total 0 0 2 100% 2 100%
(n = 2)
F normal 0 0 2 100% 2 100%
(n = 2)
F mutant 0 0 0 0 0 0
(n = 0)
G total 0 0 11 100% 0 0
(n = 11)
G normal 0 0 6 100% 0 0
(n = 6)
G mutant 0 0 5 100% 0 0
(n = 5)
Sum 263 69.21% 108 28.42% 11** 2.89%
*In a total 383 isolates, three (two mutant isolates from genotype D and one from E) lacked both CpG island I and III, which were excluded from the distribution analysis.
**Of the remaining 380 isolates, two normal isolates of genotype F contained both two-conventional islands and novel island V, which were used twice for calculating
the rates.
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and novel islands. The rates of isolates containing different
types of islands in the total, normal and mutant groups
with genotypes A-G are shown in Table 4.
In 77 of 383 (20.13%) isolates, CpG islands II was
interrupted by an unmethylated region (6–30 bps) to form
two sections, we named "split" CpG island II (Figure 2A).
In genotype A, D, E, F and G, the rates of "split" island II
were 2% (3/150), 30.2% (60/199), 28.6% (4/14), 50% (1/2)
and 90.9% (10/11), respectively (Table 5). This “split”
phenomenon was also detected in CpG island I from 8
isolates (2.1%) (Figure 2B). In genotype D and E, the rates
of "split" island I were 3.5% (7/199) and 7.1% (1/14), re-
spectively (Table 5). In addition, two mutant isolates of
genotype D (GQ477456 and AB674414) and one mutant
isolate of genotype E (GU563552) lacked both CpG islands
I and III (Table 5). A nonfunctional pre-C/C protein was
observed in GQ477456, and nonfunctional pre-C/C, poly-
merase and large/middle S proteins were detected in
GU563552. In AB674414, the “misc_feature”, a region
of biological significance, was detected.Comparison of CpG island length between normal and
mutant isolates
In genotype A, the length differences (LDs) of islands I,
II, III and IV between the normal and mutant isolates
were 8, 128, 14 and 1 bp, and the percent differences
(PDs) of normal CpG length were 3.85%, 22.7%, 4.96%
and 0.96%, respectively. In genotype D, LDs of islands I,
II, III and IV were 254, 128, 99 and 45 bp, and the PDs
were 249%, 22.3%, 55.31% and 44.12%, respectively. In
genotype E, the LDs of islands II and III were 24, and
175 bp, and the PDs were 5.2% and 61.4%, respectively.
In genotype G, the LDs of islands II and III were 3 and
46 bp, and the PDs were 0.64% and 23.71%, respectively
(Table 6). Functional or structural abnormalities of HBV
genes were observed only in mutant isolates with either
LD of CpG islands or those without LD (Table 7).Table 5 The trait analysis of CpG islands in HBV
genotypes A-G
Genotype “Split” rates Lack rates
CpG island I CpG island II CpG islands I & III
A - 2.0% (3/150) -
B - - -
C - - -
D 3.5% (7/199) 30.2% (60/199) 1.0% (2/199)
E 7.1% (1/14) 28.6% (4/14) 7.1% (1/14)
F - 50.0% (1/2) -
G - 90.9% (10/11) -Discussion
Geographical distribution of HBV genotypes in Europe
Of the 383 HBV isolates obtained from European patients,
the most frequent was genotype D, followed by genotype
A, in accordance with the previous reports on the geo-
graphical distribution of HBV genotypes in Europe, es-
pecially the western part of Europe [7,10-12,21-23].
Genotype A was observed in 7 countries and genotype
D in 12 countries. All other minor occurring genotypes
including B, C, E, F and G, were found in 7 countries
(Figure 1). Of these countries, Belgium had the great-
est genotypic variation (A, B, C, D, E and G). The
highest rates of HBV isolates in all genotypes (29.24%,
112/383), especially genotype A (48%, 72/150) were
also found in Belgium. This might be explained by
recent immigration from Far East Asia and Africa
to Europe [24] and indicates Belgium, as a Western
European country, has had an increased rate of HBV in-
fections during the last decade [2]. For genotype D, the
highest rate of HBV isolates was found in Turkey, which
might be because Turkey has served as a bridge for many
migration events during history [23].
Mutations among genotypes in Europe
In the present study, the highest rates of mutant isolates
occurred in genotypes D (46.7%) and G (45.5%). These
mutations were associated with structural or functional
abnormalities of the HBV genes. In genotype D, most
significant functional abnormalities occurred in the pre-
C/C region that include the truncated pre-C/C protein,
the nonfunctional pre-C/C protein, or pre-C/C proteins
containing an aa internal deletion. These abnormal
changes might result from a point mutation occurring in
the pre-C/C region or from pre-C/C genes becoming
pseudogenes. It was shown that pre-C/C genes in some
isolates of genotype D contained a point mutation at
position 1896 (G to A) that resulted in a premature stop
codon (TGG to TAG) at the end of the precore region,
preventing Hepatitis B e antigen (HBeAg) synthesis [25].
Lack of circulating HBeAg, an immune tolerogen, might
contribute to a more aggressive disease and cause liver
damage with progression to cirrhosis and cancer or ful-
minant hepatitis [4,17,25]. This might explain why geno-
type D is associated with more severe liver diseases [4].
Genotype G infection was often detected in the context
of co-infection with human immunodeficiency virus
(HIV) or recombination with genotype A [26]. It is char-
acterized by stop codons at codon 2 and 28 of the pre-C
region and insertion of 36 nucleotides at the 5' end of
the C gene [8] and by mutations preventing expression
of HBeAg [27]. In the present study, 54.5% (6/11) of
genotype G isolates were from patients co-infected with
HIV. The mutations occurred in the pre-C/C and X
gene regions and led to the nonfunctional pre-C/C
Table 6 The length differences of CpG islands between normal and mutant isolates in HBV Genotypes A-G
Genotype CpG island I CpG island II CpG island III CpG island IV CpG island V
























A (n = 123)
Normal
78-285 208 8 (3.85%) 1113-1676 564 128 (22.7%) 2185-2466 282 14 (4.96%) 529-632 104 1 (0.96%) - - -
A (n = 27)
Mutant
76-291 216 1228-1663 436 2196-2463 268 530-632 103 - -
B (n = 6)
Normal
108-287 180 - 1139-1683 545 - 2298-2462 165 - - - - - - -
B (n = 0)
Mutant
- - - - - - - - - -
C (n = 1)
Normal
186-286 101 - 1219-1663 445 - 2280-2442 263 - - - - - - -
C (n = 0)
Mutant
- - - - - - - - - -
D (n = 106)
Normal
185-286 102 254 (249%) 1100-1674 575 128 (22.3%) 2265-2443 179 99 (55.31%) 454-555 102 45 (44.12%) - - -
D (n = 93)
Mutant
77-432 356 1191-1637 447 2188-2465 278 443-589 147 - -
E (n = 12)
Normal
72-286 215 - 1212-1674 463 24 (5.2%) 2172-2456 285 175 (61.4%) 471-583 113 - - - -
E (n = 2)
Mutant
- - 1230-1668 439 2334-2443 110 - - - -
F (n = 2)
Normal
- - - 1216-1673 458 - 2298-2458 161 - - - - 1921-2038 118 -
F (n = 0)
Mutant
- - - - - - - - - -
G (n = 6)
Normal
- - - 1160-1628 469 3 (0.64%) 2304-2497 194 46 (23.71%) - - - - - -
G (n = 5)
Mutant
- - 1163-1628 466 2350-2497 148 - - - -












Table 7 The relationship between the abnormalities and length differences of CpG islands and mutations in HBV
Genotypes A-G
Genotype Island I Island II Island III Island IV Island V
LD-Y LD-N LD-Y LD-N LD-Y LD-N LD-Y LD-N LD-Y LD-N
A + + - + - + - + - -
D + + - + + + + - - -
E - - - + - + - + - -
G - - - + - + - - - -
All functional or structural abnormalities of HBV genes are observed in the mutant isolates not in the normal isolates.
LD-Y: lengths of CpG islands between normal and mutant isolates are different. LD-N: lengths of CpG islands between normal and mutant isolates are not different.
+: The functional or structural abnormalities of HBV genes are observed; −: The functional or structural abnormalities of HBV genes are not observed.
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frequent finding of genotype G in co-infected patients and
its association with more advanced fibrosis suggests this
genotype leads to rapid liver disease progression [28].
Comparison of CpG island length between normal and
mutant isolates
Some studies have reported that the lengths of CpG
islands in mammalian genomes exhibit substantial vari-
ation. Because promoters with long CpG islands have a
larger number of RNA polymerase II binding sites com-
pared to promoters with short CpG islands, it was proposed
that variations in the length of CpG island promoters is
tightly linked to patterns of downstream gene expression
[29]. In the present study, the LDs of CpG islands between
the normal and mutant isolates were observed in genotypes
A, D, E and G. Although the functional abnormalities of
HBV genes were detected in some of the mutant isolates
with LDs of islands, such abnormalities were also found in
some mutant isolates without island LDs. Because all abnor-
malities were observed in the mutant isolates, such abnor-
malities should be caused by a mutation in isolates but not
by the LD of the island. However, the biological and clinical
significance of LD of islands warrants further study as
islands located in the regulatory region are critical for
transcription.
Novel CpG islands in HBV genotypes A-G
The three novel CpG islands in the HBV genome were
first described by Zhang et al., and were thought to be
potential targets for DNA methylation [6]. We also
found novel islands at the same locations in the HBV
genome. In our study, novel island IV was present in ge-
notypes A, D and E, island V was present in genotype F;
and island VI was not present in A-G genotypes. In the
report by Zhang et al., island IV was detected in geno-
types B, C and D, island V in genotypes B, F and H, and
island VI in genotype C. The reason for differences be-
tween both studies might be that data was obtained from
different sources. Our data were from 383 isolates of
European patients, and Zhang's data was from 176 rep-
resentative isolates of patients residing in 48 differentcountries worldwide. In our study, island IV was located
between CpG islands I and II and upstream of Enh I, a
region overlapping the S and P gene, island V was lo-
cated between islands II and III, close to Enh II and the
core promoters, a region overlapping the C genes. Based
on their position, their methylation status might be asso-
ciated with the transcription of HBV genes. To date,
there is no experimental data on the relationship be-
tween the methylation status of novel islands and ex-
pression of HBV genes, which requires further study.
Distribution and genetic trait of CpG islands in HBV
genotypes A-G
The various distributions of CpG islands in different ge-
notypes were observed in this study. Island I was ob-
served in genotypes A, B, C, D and E, and islands II and
III were detected in all A-G genotypes. These results
were similar to a previous study [6]. The reason for
some isolates only containing islands II and III might be
the density of CpG dinucleotides within the first CpG-
rich region in those sequences being low, leading to a
loss of island I [6]. Because HBV DNA is methylated in
human tissues either as a nonintegrated or integrated
form [14,15] and DNA methylation is CpG site-specific
[30], the density and location of HBV CpG islands could
have a direct impact on HBV gene expression in human
tissue through their methylation.
We found “split” CpG islands in 77 of 383 (20.13%) iso-
lates of genotypes A, D, E, F and G. This “split” phenomenon
was also detected in genotypes B and C isolated from
Chinese patients in our previous research (data not
shown). The occurrence mechanisms and the clinical sig-
nificance of “split” CpG islands I or II remain unclear. In
this study we found that two mutant isolates of genotype
D (GQ477456 and AB674414) and one mutant isolate
from genotype E (GU563552) lacked both islands I and III
(Table 5). Island II is located in a regulatory region critical
for the transcription of covalently closed circular DNA
(cccDNA), island I spans the start site of the S gene, and
island III covers the partial C gene and encompasses the
start site of the P gene, therefore by investigating their
methylation and mutation status, further insights into the
Zhong et al. BMC Bioinformatics  (2015) 16:38 Page 10 of 11mechanism of regulatory complexity of gene expression
and clinicopathology might be obtained.
Conclusions
HBV genotypes A-G were identified in 383 isolates from
European patients and the most frequent were genotypes
D and A, followed by E, G, B, F and C. Higher rates of
mutant isolates were observed in genotypes D and G,
and isolates lacking both CpG islands I and III were ob-
served in genotypes D and E. Mutations in the genotypes
might affect the regulation of HBV gene expression,
leading to different clinical outcomes. The findings in
this study will aid our understanding of the impact of
mutation on HBV gene expression among genotypes and
the potential role of CpG islands in the epigenetic regu-
lation of the HBV genome. A limitation of the current
work was the small number of isolates in some genotypes,
especially genotypes B, C and F, which should be cumula-
tively increased to obtain more complete information.
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